[{"id":"0300bd11-3c88-4727-a08a-0abd664e0d55","acronym":"","url":"https://clinicaltrials.gov/study/NCT05773326","created_at":"2023-03-17T14:02:34.285Z","updated_at":"2024-07-02T16:35:02.449Z","phase":"Phase 1","brief_title":"Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG","source_id_and_acronym":"NCT05773326","lead_sponsor":"Nader Sanai","biomarkers":" PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation","tags":["PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-05-21"},{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"c059badf-8a2b-4247-bace-32ba3408645c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03317119","created_at":"2021-01-18T16:22:52.836Z","updated_at":"2024-07-02T16:35:11.068Z","phase":"Phase 1","brief_title":"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03317119","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF • PIK3CA • PTEN","pipe":" | ","alterations":" BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type • PIK3CA mutation + PTEN mutation","tags":["BRAF • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/11/2018","start_date":" 04/11/2018","primary_txt":" Primary completion: 07/14/2023","primary_completion_date":" 07/14/2023","study_txt":" Completion: 07/14/2023","study_completion_date":" 07/14/2023","last_update_posted":"2024-04-08"},{"id":"7b687780-b61c-439e-9b4e-196b803f25c3","acronym":"PAveMenT","url":"https://clinicaltrials.gov/study/NCT04360941","created_at":"2023-12-22T20:17:07.096Z","updated_at":"2024-07-02T16:35:25.341Z","phase":"Phase 1","brief_title":"PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","source_id_and_acronym":"NCT04360941 - PAveMenT","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" PD-L1 • PIK3CA • TMB • PTEN • RB1","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation • PD-L1 negative • RB1 mutation • PTEN expression • PIK3CA expression • PIK3CA mutation + PTEN mutation","tags":["PD-L1 • PIK3CA • TMB • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation • PD-L1 negative • RB1 mutation • PTEN expression • PIK3CA expression • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 08/11/2020","start_date":" 08/11/2020","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-12-22"},{"id":"f7ef3a32-c39e-4a8b-ba39-902767a7f32b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01195376","created_at":"2021-01-18T04:47:04.621Z","updated_at":"2024-07-02T16:36:37.555Z","phase":"Phase 1","brief_title":"A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01195376","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dactolisib (RTB101)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2020-12-09"},{"id":"f984c669-5c9b-447e-b95e-48bf7957acd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01277757","created_at":"2021-01-18T05:10:57.904Z","updated_at":"2024-07-02T16:37:04.571Z","phase":"Phase 2","brief_title":"Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT01277757","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PIK3CA • PTEN","pipe":" | ","alterations":" ER positive • PIK3CA mutation • EGFR positive • PIK3CA mutation + PTEN mutation","tags":["ER • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • EGFR positive • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2018-12-19"}]